EU and US could reach trade deal this weekend - Reuters
Biolife Solutions Inc. (NASDAQ:BLFS), a biotech company with a market capitalization of $1.17 billion and a "Good" InvestingPro Financial Health score, saw its Chief Technology Officer Sean Werner recently sell company stock valued at approximately $5,576, according to a filing with the Securities and Exchange Commission. The transactions were executed over two days.
On March 3, Werner sold 136 shares at an average price of $25.46, totaling $3,462. The following day, March 4, he sold an additional 88 shares at an average price of $24.03, amounting to $2,114. The stock currently trades at $26.25, with analysts setting price targets between $30 and $34, suggesting potential upside.
The sales were conducted under a Rule 10b5-1 trading plan, which was established to cover tax obligations related to the vesting of restricted stock. Following these transactions, Werner holds 4,865 shares of Biolife Solutions. For comprehensive insider trading analysis and additional insights, access the detailed Pro Research Report available on InvestingPro.
In other recent news, BioLife Solutions reported strong fourth-quarter results, with revenues of $22.7 million, surpassing analyst expectations of $22.03 million. The company also posted a narrower-than-expected loss of $0.04 per share, compared to the anticipated loss of $0.08 per share. The Cell Processing segment was a significant contributor, with a 37% year-over-year increase in revenue to $20.3 million. Benchmark maintained a Buy rating for BioLife Solutions, setting a price target of $30, based on these positive earnings and the company’s robust growth potential. BioLife’s management has issued optimistic guidance for 2025, projecting revenue growth of 16% to 20%, with expectations to reach $95.5 million to $99 million. The company also forecasts Cell Processing revenue to rise by 18% to 21%, reaching $86.5 million to $89 million. Additionally, BioLife’s biopreservation media is currently integrated into 17 approved cell and gene therapies, with further approvals anticipated in the coming year. These developments highlight BioLife’s strategic focus on its core business following recent divestitures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.